The CoV-2 outbreak: how hematologists could help to fight Covid-19

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorGalimberti, Sara-
Autor(es): dc.creatorBaldini, Chiara-
Autor(es): dc.creatorBaratè, Claudia-
Autor(es): dc.creatorRicci, Federica-
Autor(es): dc.creatorBalducci, Serena-
Autor(es): dc.creatorGrassi, Susanna-
Autor(es): dc.creatorFerro, Francesco-
Autor(es): dc.creatorBuda, Gabriele-
Autor(es): dc.creatorBenedetti, Edoardo-
Autor(es): dc.creatorFazzi, Rita-
Autor(es): dc.creatorBaglietto, Laura-
Autor(es): dc.creatorLucenteforte, Ersilia-
Autor(es): dc.creatorDi Paolo, Antonello-
Autor(es): dc.creatorPetrini, Mario-
Data de aceite: dc.date.accessioned2026-02-09T12:13:26Z-
Data de disponibilização: dc.date.available2026-02-09T12:13:26Z-
Data de envio: dc.date.issued2020-05-27-
Data de envio: dc.date.issued2020-05-27-
Data de envio: dc.date.issued2020-07-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41256-
Fonte completa do material: dc.identifierhttp://www.sciencedirect.com/science/article/pii/S1043661820311749-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1156947-
Descrição: dc.descriptionCOVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourcePharmacological Research-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectRuxolitinib-
Palavras-chave: dc.subjectTyrosine kinase inhibitors (TKIs)-
Palavras-chave: dc.subjectBegelomab-
Palavras-chave: dc.subjectBaricitinib-
Palavras-chave: dc.subjectTocilizumab-
Palavras-chave: dc.subjectAcute graft-versus-host disease (aGVHD)-
Palavras-chave: dc.subjectMacrophage activation syndrome (MAS)-
Título: dc.titleThe CoV-2 outbreak: how hematologists could help to fight Covid-19-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.